- Home
- MQ vs AUPH Comparison
MQ vs AUPH Comparison
Compare MQ & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MQ | AUPH |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MQ | AUPH |
|---|---|---|
| Price | $4.43 | $15.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $5.36 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 2.6M | 980.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | ★ $624,884,000.00 | $283,055,000.00 |
| Revenue This Year | $16.89 | $17.54 |
| Revenue Next Year | $16.36 | $15.74 |
| P/E Ratio | ★ N/A | $7.76 |
| Revenue Growth | ★ 23.25 | 20.38 |
| 52 Week Low | $3.70 | $7.29 |
| 52 Week High | $7.04 | $16.88 |
Technical Indicators
Market Signals| Indicator | MQ | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 61.13 | 46.81 |
| Support Level | $4.37 | $14.56 |
| Resistance Level | $4.50 | $16.32 |
| Average True Range (ATR) | 0.14 | 0.52 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 84.62 | 9.52 |
Price Performance
Historical ComparisonAbout MQ Marqeta Inc.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.